ASX - Delayed Quote AUD

Imagion Biosystems Limited (IBX.AX)

Compare
0.0200
+0.0020
+(11.11%)
As of 4:10:59 PM GMT+11. Market Open.
Loading Chart for IBX.AX
DELL
  • Previous Close 0.0180
  • Open 0.0180
  • Bid 0.0200 x --
  • Ask 0.0180 x --
  • Day's Range 0.0180 - 0.0200
  • 52 Week Range 0.0180 - 0.3400
  • Volume 668,325
  • Avg. Volume 883,584
  • Market Cap (intraday) 4.027M
  • Beta (5Y Monthly) 1.98
  • PE Ratio (TTM) --
  • EPS (TTM) -0.1800
  • Earnings Date Feb 28, 2025 - Mar 5, 2025
  • Forward Dividend & Yield --
  • Ex-Dividend Date --
  • 1y Target Est --

Imagion Biosystems Limited provides medical imaging technologies using magnetic resonance. It has activities in nanotechnology; biotechnology; cancer diagnostics; and superparamagnetic relaxometry. The company develops MagSense, which is in Phase I clinical trials for the treatment of HER2 breast cancers, as well as in preclinical stage to treat prostate, ovarian, brain, and pancreatic cancer. It also develops PrecisionMRX, an iron oxide nanoparticle to detect cancer. The company has a collaborative research program with Patrys Limited and The University of Sydney. Imagion Biosystems Limited was incorporated in 2016 and is based in South Melbourne, Australia.

imagionbiosystems.com

--

Full Time Employees

December 31

Fiscal Year Ends

Recent News: IBX.AX

View More

Performance Overview: IBX.AX

Trailing total returns as of 1/7/2025, which may include dividends or other distributions. Benchmark is

.

YTD Return

IBX.AX
13.04%
S&P/ASX 200 [XJO]
1.54%

1-Year Return

IBX.AX
93.94%
S&P/ASX 200 [XJO]
10.63%

3-Year Return

IBX.AX
99.31%
S&P/ASX 200 [XJO]
11.16%

5-Year Return

IBX.AX
98.39%
S&P/ASX 200 [XJO]
21.37%

Compare To: IBX.AX

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: IBX.AX

View More

Valuation Measures

As of 1/7/2025
  • Market Cap

    4.03M

  • Enterprise Value

    6.83M

  • Trailing P/E

    --

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    0.34

  • Price/Book (mrq)

    --

  • Enterprise Value/Revenue

    3.64

  • Enterprise Value/EBITDA

    --

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    -106.79%

  • Return on Assets (ttm)

    -109.93%

  • Return on Equity (ttm)

    --

  • Revenue (ttm)

    5.92M

  • Net Income Avi to Common (ttm)

    -6.32M

  • Diluted EPS (ttm)

    -0.1800

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    382.45k

  • Total Debt/Equity (mrq)

    --

  • Levered Free Cash Flow (ttm)

    -1.33M

Research Analysis: IBX.AX

View More

People Also Watch